Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib

Publisher： Karger

E-ISSN： 1423-0232|89|4|235-241

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.4, 2015-06, pp. : 235-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 52-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Nomogram for Disease-Free Survival in Patients with Renal Adenocarcinoma

By  

Urologia Internationalis, Vol. 88, Iss. 3, 2012-02 ,pp. : 271-276

Karger

Access to resources Recommend Favorite

Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 121-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 90, Iss. 3, 2016-02 ,pp. : 119-126

Karger

Access to resources Recommend Favorite

An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 342-350

Karger

Access to resources Recommend Favorite